IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ — Masimo (Nasdaq:
MASI) announced today that over 20 new clinical studies
showcasing Masimo noninvasive patient monitoring technologies were
presented last week at the American Society of
Anesthesiologists (ASA) Annual Meeting in San Diego,
California. The largest gathering of anesthesiologists in the
world, the ASA Annual Meeting provides an important platform for
previewing the latest in medical developments and clinical research
to industry thought-leaders.
Noninvasive and Continuous Hemoglobin (SpHb®)This year,
10 new clinical studies examining the accuracy and clinical utility
of SpHb monitoring in a variety of patient populations were
conducted and presented by a variety of researchers from leading
institutions around the world. Dr. Jesse Ehrenfeld, in an
NIH-funded randomized controlled trial, showed SpHb monitoring
reduced the frequency of intraoperative transfusions by 86% (0.6%
vs. 4.5%)(1) while Dr. Ronald Miller, from the University of
California-San Francisco, confirmed its value in transfusion
medicine, concluding that SpHb may “facilitate the decision as to
whether blood should be administered”(2) and Dr. Lionel Lamhaut,
after evaluating patients undergoing urologic surgery using SpHb
monitoring in a study conducted at Necker University Hospital in
Paris, France, suggested “daily use of this technology.”(3)
Several studies highlighted the accuracy of SpHb monitoring,
including Dr. Chunyuan Qui from Kaiser Permanente who, in the first
multi-center study of SpHb in a large integrated healthcare
delivery network, evaluated its accuracy “over a wide range of
hemoglobin values” and concluded SpHb “has the significant
potential to facilitate real time decisions and to avoid the
complications, expense
‘/>”/>
SOURCE